<DOC>
	<DOCNO>NCT00079989</DOCNO>
	<brief_summary>To evaluate safety efficacy tigecycline treatment subject select serious infection cause resistant gram-negative bacteria , eg , Acinetobacter baumannii , Enterobacter specie , Klebsiella pneumoniae resistant gram-negative pathogen , antibiotic fail tolerate appropriate antimicrobial therapy . The primary efficacy endpoint clinical response .</brief_summary>
	<brief_title>Study Evaluating Tigecycline Selected Serious Infections Due Resistant Gram-Negative Organisms</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Gram-Negative Bacterial Infections</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Male female subject age 18 year old Isolation resistant gramnegative pathogen , eg , Enterobacter specie , Acinetobacter baumannii , Klebsiella pneumoniae , resistant gramnegative pathogen , alone 1 isolate polymicrobial infection Resistant gramnegative organism define likely presence ESBL related mechanism limit therapeutic alternative treatment complicate infection Subjects concomitant condition take concomitant medication , opinion investigator , could preclude evaluation response make unlikely contemplated course therapy followup assessment complete substantially increase risk associate subject 's participation study Anticipated length antibiotic therapy &lt; 7 day Known suspected hypersensitivity tigecycline compound related class antibacterial agent ( eg , tetracycline , minocycline , doxycycline )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Bacterial Infections</keyword>
</DOC>